CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-08-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellleukemiaadvancedchemotherapystandard
  Phrases that lowered it: safety ofcellscombinationtypepositive
• Sponsor's past termination rate: 27.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 166 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 29.3% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor's past trials: 419 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 80 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 97.2% (raises risk) · Drug's FDA history
• Keywords listed: 15 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab NCT01416974 · started 2011 · scored riskier than 52% of active trials completed
• CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies NCT02529813 · started 2015 · scored riskier than 84% of active trials completed
• CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy NCT01029366 · started 2010 · scored riskier than 73% of active trials completed
• CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies NCT00968760 · started 2011 · scored riskier than 78% of active trials completed
• T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies NCT02659943 · started 2016 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.